Back to search
FDAFDA · Food and drugs·Recall number D-0219-2019

Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99

Published November 14, 2018 · Recall initiated: October 5, 2018

Summary

FDA records drug Class III recall D-0219-2019, published November 14, 2018 and initiated October 5, 2018. Recalling firm: Orexigen Therapeutics, Inc.; Status: Terminated; Reported quantity: 18,895 bottles; Lot: Lot #: ZYCY, Exp. 04/11/2021. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Container packaging defect.

What to do

Voluntary: Firm initiated · Letter

Get an email if CONTRAVE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
CONTRAVE
Manufacturer
Orexigen Therapeutics, Inc.
Distributor
Within the United States
UPC
0351267890997
Lot
Lot #: ZYCY, Exp. 04/11/2021
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Contrave (naltrexone HCl and bupropion HCl). Extended-Release Tablets, 8mg/90 mg, 120-count bottles, Rx only, Distributed by Orexigen therapeutics, Inc., La Jolla, CA 92037, NDC 51267-890-99 recalled?

Yes. FDA published recall D-0219-2019 on November 14, 2018. Reported hazard: Container packaging defect.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: CONTRAVE. UPC: 0351267890997.